Edesa Biotech, Inc. (EDSA) Stock Ticker
Market factors today
Unlock the full EDSA picture
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
EDSA stock facts
| Ticker symbol | EDSA |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $38.6M |
| CEO | Pardeep Nijhawan |
| Employees | 17 |
| Headquarters | Markham, ON, CA |
| IPO date | 2010-06-21 |
| Website | www.edesabiotech.com |
What you can see for EDSA on Tickr
Live EDSA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the EDSA report.
Rankings
FAQ
What is the ticker symbol for Edesa Biotech, Inc.?
The ticker symbol for Edesa Biotech, Inc. is EDSA, listed on the NASDAQ Capital Market.
What is EDSA?
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients,…